Iron deficiency anemia is a common complication of chronic kidney disease (CKD). CKD
patients suffer from both absolute and functional iron deficiency. Absolute iron deficiency is …

Anaemia is a common consequence of chronic kidney disease (CKD); however, the risk
factors for its development and its impact on outcomes have not been well synthesised …

Abstract Background Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor
(HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In …

Results Of the 145 patients enrolled, 143 were evaluable for efficacy. Overall, 92% of
patients achieved hemoglobin response. Higher compared with lower starting doses led to …

Background Whether correction of anemia in patients with stage 3 or 4 chronic kidney
disease improves cardiovascular outcomes is not established. Methods We randomly …

Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …

Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …

Although renal osteodystrophy and vitamin D analogs may be related to survival in
maintenance hemodialysis (MHD) patients, most studies have examined associations …

Trials of anemia correction in chronic kidney disease have found either no benefit or
detrimental outcomes of higher targets. We did a secondary analysis of patients with chronic …

Background Iron supplementation is crucial for the treatment of anemia of chronic kidney
disease (CKD). Although intravenous (IV) iron is preferred for patients with CKD receiving …